The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted ag...

Full description

Saved in:
Bibliographic Details
Published in:Clinical breast cancer 2022-04, Vol.22 (3), p.223-234
Main Authors: Twelves, Chris, Bartsch, Rupert, Ben-Baruch, Noa Efrat, Borstnar, Simona, Dirix, Luc, Tesarova, Petra, Timcheva, Constanta, Zhukova, Lyudmila, Pivot, Xavier
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - pathology
Chemotherapy
Cytotoxic
Female
HR positive
Humans
Metastatic breast cancer
Neoplasm Metastasis
Receptor, ErbB-2 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines current HR-positive/HER2-negative MBC clinical guidelines and addresses key questions around the use of chemotherapy in the face of emerging therapeutic options. Specifically, the indications for chemotherapy in patients with HR-positive/HER2-negative MBC and the choice of optimal chemotherapy are discussed.
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2021.10.007